Senior Oncology Clinical Development Director

Exelixis Inc; United States; In loco; USD 255.000 - 361.000; Tempo pieno

Vantaggi offerti da questo lavoro

401k plan

Medical coverage

Dental & Vision

Life insurance

Disability insurance

Flex spending accounts

Bonus program

Stock purchase

Long-term incentives

Vacation days

Holidays

Sick days

Descrizione del lavoro

Exelixis Inc is seeking an MD with oncology credentials to lead and execute oncology trials in development. You will design studies, monitor safety, and work with cross-functional teams to interpret results and prepare regulatory reports.

Ideal candidates have 5+ years post-residency, biotech/pharma drug development experience, and strong communication. Competitive compensation includes comprehensive benefits and annual bonus opportunities.

Competenze

• MD with board certification or eligibility in Oncology preferred.
• Drug development experience in biotech or pharma desirable.
• Hands-on design, execution and reporting of oncology trials.

Mansioni

• Lead and execute early/late stage oncology trials in development.
• Act as medical monitor for company-sponsored trials.
• Collaborate with safety and cross-functional teams on data review.
• Interpret trial data and prepare reports for agencies and publications.
• Recruit clinical investigators and coordinate protocols and reports.

Conoscenze

Clinical trial leadership

Regulatory knowledge

Cross-functional collaboration

Scientific communication

Analytical thinking

Formazione

MD with board certification/eligibility in Oncology

Descrizione del lavoro

Exelixis Inc is seeking an MD with oncology credentials to lead and execute oncology trials in development. You will design studies, monitor safety, and work with cross-functional teams to interpret results and prepare regulatory reports.

Ideal candidates have 5+ years post-residency, biotech/pharma drug development experience, and strong communication. Competitive compensation includes comprehensive benefits and annual bonus opportunities.